On Unmet Need
Paul Romness: Osteosarcoma is a devastating disease that primarily affects young people. Treatment options have not changed significantly in decades, and survival rates for metastatic disease remain poor. These patients deserve better, and that drives our mission.
Beyond the human imperative, osteosarcoma represents an attractive drug development opportunity. Strong FDA support for pediatric cancers, orphan drug incentives, and a clear path to approval create a favorable development environment.
On Lead Program
Q: Tell us about your immunotherapy approach?
Paul Romness: Our lead program targets osteosarcoma through novel immunotherapy mechanisms designed to overcome tumor resistance. Osteosarcomas have historically been resistant to immunotherapy, but our approach attacks the tumor’s defense mechanisms directly.
Early clinical data has been encouraging, with responses in patients who have exhausted other options.
On Patient Focus
Q: How do patients shape your work?
Paul Romness: Everything we do is driven by patients and families affected by this disease. We work closely with patient advocacy groups and regularly hear from families about their experiences. Their courage and resilience inspire our team every day.
We also involve patients in clinical trial design to ensure our programs are patient-friendly and address their real needs.
On Development Timeline
Q: What milestones should we expect?
Paul Romness: We expect to report additional clinical data in 2026 that will further demonstrate proof of concept. Depending on results, we could initiate registrational studies in the following year.